In conclusion, considering the importance of identifying biomarkers to discriminate between different neurological disorders characterized by cognitive impairment, the present study proposes the clinical potential of adding CSF orexin-A levels to the list of CNS biomarkers already measured in patients with neurocognitive disorders, in the view of developing a precision medicine-based approach. Here, HCRT is linked to nervous system disorder.